2023年3月13日

2023年3月10日QurAlis公司临床分期生物科技公司发展突破精密的肌萎缩性脊髓侧索硬化症(ALS)药物和其他神经退行性疾病与基因验证目标,今天宣布它已经关闭了一个系列B超额认购8800万美元融资,使总资金为1.435亿美元。融资是由EQT生命科学,LSP痴呆的投资基金,赛诺菲安万特公司,和Droia企业,ALS的参与投资基金和现有投资者LS北极星创新基金,任务BioCapital INKEF资本,痴呆发现基金,安进公司,议员医疗风险管理、三井全球投资,杜比家庭企业使命湾资本,桑福德生物科学。所得资金将基金qrl的临床开发- 201和qrl - 101年,公司的主要产品在ALS候选人。此外,融资将支持正在进行的和计划的研究,以及促进QurAlis的管道与基因治疗ALS的候选人这一目标特定的组件和相关的额颞叶痴呆(FTD)病理学和定义ALS患者群体根据致病基因突变(s)和临床生物标志物。作为系列B融资的一部分,希金博士,董事总经理EQT生命科学,和拉娅克雷斯波,博士,赛诺菲安万特公司的合伙人将加入QurAlis的董事会。“这融资反映重要的投资者信心QurAlis背后的科学的新一代精密的药品,世界级的团队,和承诺带来新疗法的病人患有肌萎缩性侧索硬化症和其他神经退行性疾病,”安妮·c·惠特克说,椅子QurAlis的董事会。“我们很幸运由这群优秀的投资者分享我们对神经退行性疾病患者的承诺和我们的愿景来阻止疾病进展和显著改善的结果,“Kasper Roet说QurAlis博士,首席执行官和创始人之一。“这轮融资承认我们的科学记录,将帮助我们推进我们两个铅的临床开发项目ALS和健壮的管道通过短期的价值创造的里程碑。我们科学突破的障碍寻求带来急需的精密治疗病人。”“QurAlis突出作为一个领域的领导人与下一代精密神经退行性疾病药物和基因验证目标,”菲利普Scheltens医学博士说博士,EQT生命科学的LSP痴呆基金。 “We are extremely excited to join this distinguished group of investors supporting this world-class team to advance what we believe could become life-changing treatments for patients and their families.” QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. QRL-201 recently entered the clinic in the first-ever clinical trial to evaluate a therapy that rescues STMN2 in people with ALS (ANQUR; NCT05633459). QRL-201 is the second program in QurAlis’ pipeline to enter the clinic recently. In December 2022, QurAlis announced the Company initiated dosing of QRL-101 in a first-in-human Phase 1 clinical trial (NCT05667779). QRL-101 is a first-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS. About QurAlis Corporation QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. QurAlis’ proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a deep pipeline of antisense oligonucleotides and small molecule programs including addressing sub-forms of ALS that account for the majority of ALS patients. For more information, please visit www.quralis.com or follow us on Twitter @QurAlisCo.